Joseph Palamar

Mar 23, 2024 | ajpmonline.org | Joseph Palamar

Introduction While morbidity and mortality related to synthetic opioids such as illicitly manufactured fentanyl (IMF) are monitored in the U.S., there has been a lack of national survey data focusing on use. Survey data are important as self-report can help estimate prevalence of use among living persons.

Jan 3, 2024 | jamanetwork.com | Samuel T. Wilkinson |Joseph Palamar |Gerard Sanacora

The Rapidly Shifting Ketamine Landscape in the US In recent years, ketamine has been hailed as a miracle treatment for depression and related disorders. The US Food and Drug Administration (FDA) approved the S-enantiomer of ketamine, esketamine, as the first antidepressant in a new class for treatment-resistant depression in 2019.1 Emerging evidence suggests that the landscape of ketamine both as a medical therapeutic and as a recreational substance is shifting.